PT-141

10 mg

$59.99 CAD

Bremelanotide, a melanocortin receptor agonist studied in sexual-desire signalling, with a narrowly defined approved indication in United States labelling.

Format: 10 mg
Use: Laboratory research

View cart

For laboratory research only · Not for human consumption

What is PT-141?

PT-141 is bremelanotide, described as a melanocortin receptor agonist. An approved United States formulation exists with specific labelling; this listing is laboratory research material and is not that product.

Key concepts: Receptor · Agonist · Endpoint

How it works and what researchers study

Research in this area examines melanocortin receptor signalling and sexual-desire endpoints in defined populations. Labelling for the approved formulation also documents adverse reactions and precautions.

What the evidence shows

United States labelling covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with stated exclusions, and notes that the mechanism for that indication is not fully known. Transient blood-pressure increases, nausea and hyperpigmentation are described among relevant considerations.

Limits of the evidence

The approved indication does not extend to men, to postmenopausal women, or to performance enhancement.
The mechanism for the labelled indication is described as not fully established, so precise pathway claims go beyond the source.
United States labelling implies nothing about Canadian authorization, and describes the approved formulation rather than this research vial.

References

Official United States prescribing information for bremelanotide injection (Vyleesi), revised March 2024. United States labelling only. View source
Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada. View source

Compound science vs product quality

The research described here studied the compound under laboratory or clinical conditions. No cited paper or label tested a Proof Line Peptides vial. Product-level questions — identity, stated quantity and lot-matched documentation — are answered by records supplied with the material, not by published studies.

Questions about PT-141

Is PT-141 approved for men?: No. The United States approved indication covers acquired, generalized hypoactive sexual desire disorder in premenopausal women, with exclusions.
Is the mechanism fully understood?: Labelling describes melanocortin receptor agonism but states the mechanism for the labelled indication is not fully known.
Are there notable safety considerations in labelling?: Yes — transient increases in blood pressure, nausea and hyperpigmentation are among the considerations described.